Xenetic Biosciences Partners with Tokyo Medical University for Cancer Research

Xenetic Biosciences, Inc., a biopharmaceutical company, has entered a Materials Transfer Agreement with Tokyo Medical University. This collaboration focuses on using Xenetic's recombinant DNase I to study its effectiveness against Ewing sarcoma, a rare pediatric cancer.

The agreement will see Professor Takuro Nakamura leading research on the combination of DNase I and chemotherapy in a preclinical mouse model of Ewing sarcoma. This model reflects the characteristics of human Ewing sarcoma, a cancer with a low five-year survival rate for relapsed cases.

Previous studies have highlighted the role of neutrophil extracellular traps (NETs) in poor prognosis for Ewing sarcoma patients. Xenetic's DNase I aims to reduce NETs, potentially enhancing chemotherapy efficacy.

This partnership underscores Xenetic's commitment to advancing its DNase program, part of its strategy to explore new immuno-oncology treatments.